PMC5088549_01
A chest X-ray taken on admission. Diffuse infiltrative shadows can be observed in both lung fields.
1349-7235-55-2855-g001.jpg
PMC5088549_01_1349-7235-55-2855-g001.jpg
g001
Although no crackles, wheezes, or rhonchi were present by chest auscultation of both lung fields, chest X-rays revealed bilateral infiltrative shadows (Fig. 1).
A chest CT scan on admission reveals mosaic patterns with bilateral ground-glass opacities and multiple nodular metastatic lesions.
1349-7235-55-2855-g002.jpg
PMC5088549_01_1349-7235-55-2855-g002.jpg
g002
A further investigation by a CT scan revealed mosaic patterns with bilateral ground-glass opacities (GGOs) (Fig. 2), which were not detected just before the administration of TAS-102.
Clinical course of the patient. Day 1 is the starting date of the first cycle of TAS-102.
1349-7235-55-2855-g003.jpg
PMC5088549_01_1349-7235-55-2855-g003.jpg
g003
Retrospectively, the patient's serum CRP and LDH levels were moderately elevated in the rest period of the 1st cycle of TAS-102, and these data improved prior to the 2nd cycle (Fig. 3).
A chest X-ray demonstrating diffuse infiltrative shadows that almost completely disappeared after treatment.
1349-7235-55-2855-g004.jpg
PMC5088549_01_1349-7235-55-2855-g004.jpg
g004
TMP-SMX and continuous betamethasone, the diffuse infiltrative shadows on her chest X-ray decreased (Fig. 4), and the respiratory failure recovered. The patient's serum beta-D glucan level on admission was significantly elevated at 90.1 pg/mL.